MyMD Pharma announces rebranding to TNF Pharmaceuticals
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
TNF Pharmaceuticals rebrands, plans mid-stage clinical trials for TNF-alpha inhibitor drug MYMD-1.
Read at seekingalpha.com
 |
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
| UBX | Unity Biotechnology | 4.17 | ||||
| NBY | NovaBay Pharmaceuticals | 3.85 | ||||
| RXRX | Recursion Pharmaceuticals | 3.58 | ||||
| GOVX | GeoVax Labs | 2.26 | ||||
| DSGN | Design Therapeutics | 2.25 | ||||
| BOLT | Bolt Biotherapeutics | 2.00 | ||||
| KZR | Kezar Life | 1.86 | ||||
| NVCT | Nuvectis Pharma | 1.53 | ||||
| XBIO | Xenetic Biosciences | 1.47 | ||||
| REPL | Replimune | 1.30 | ||||
| SRZN | Surrozen | 0.08 | ||||
| AVIR | Atea Pharmaceuticals | 0.31 | ||||
| LGND | Ligand Pharmaceuticals | 0.37 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| PASG | Passage Bio | 1.52 | ||||
| LYEL | Lyell Immunopharma | 1.61 | ||||
| ORIC | Oric Pharmaceuticals | 1.68 | ||||
| GOSS | Gossamer Bio | 2.33 | ||||
| KROS | Keros Therapeutics | 2.39 | ||||
| REVB | Revelation Biosciences | 3.23 | ||||
| LRMR | Larimar Therapeutics | 4.55 | ||||
| LYRA | Lyra Therapeutics | 5.56 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |